香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本通告全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 主席 Wenjie Zhang 香港，二零二五年十二月三日 臨時股東會通告 茲通告上海復宏漢霖生物技術股份有限公司（「本公司」）將於二零二五年十二月 三十一日（星期三）上午九時正假座中國上海市徐匯區宜州路188號B8幢10樓會議室舉 行臨時股東會（「臨時股東會」），以考慮及酌情通過下列決議案： 普通決議案 1. 考慮並酌情批准本公司與國藥控股股份有限公司於二零二五年十二月三日 訂立的經銷框架協議（「國控經銷框架協議（2025重續）」）及其項下擬進行的 交易，以及本公司日期為二零二五年十二月三日的通函所載的相關年度上 限；及授權董事於彼等認為必要時行使一切權力及進行相關其他行動及事 宜，以及簽立彼等認為或會對執行國控經銷框架協議（2025重續）項下擬進 行的交易屬必要或 ...

Core Viewpoint - The company, Fuhong Hanlin (02696.HK), has entered into a collaboration agreement with Aohong Pharmaceutical, granting exclusive commercialization rights for a product in a specified region and field [1] Group 1: Collaboration Agreement - The collaboration agreement was signed on December 3, 2025, following a memorandum of understanding established on August 7, 2025 [1] - The memorandum allowed the company to obtain exclusive commercialization rights for the licensed product in China during a transitional period before the formal agreement was signed [1] - The memorandum has been replaced by the collaboration agreement and automatically terminated on December 3, 2025 [1] Group 2: Licensed Product - The licensed product, citric acid voraselis capsule, is a CDK4/6 inhibitor approved for the treatment of HR+, HER2– breast cancer [1] - The product aligns with the company's commercialization strategy in the breast cancer sector and has commercial synergies with existing breast cancer pipeline products [1] - Introducing the licensed product will enrich the company's pipeline and enhance future revenue potential by leveraging the existing breast cancer commercialization team and resources [1]

Core Viewpoint - The company has entered into a collaboration agreement with Aohong Pharmaceutical for exclusive commercialization rights of a product in the field of HR+ and HER2– breast cancer treatment, enhancing its pipeline and revenue potential [1] Group 1: Collaboration Agreement - The collaboration agreement was signed on December 3, 2025, following a memorandum of understanding established on August 7, 2025 [1] - Aohong Pharmaceutical grants the company exclusive rights for the commercialization of the product within a specified region and field [1] - The memorandum of understanding has been replaced by the collaboration agreement and will automatically terminate on December 3, 2025 [1] Group 2: Product Details - The licensed product, citric acid voraselis capsule, is a CDK4/6 inhibitor approved for the treatment of HR+ and HER2– breast cancer [1] - The product aligns with the company's commercialization strategy in the breast cancer sector and has commercial synergy with existing breast cancer pipeline products [1] - Introducing this licensed product will enrich the company's pipeline and leverage its existing breast cancer commercialization team and resources to enhance future revenue scale [1]

此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢股票經紀或其他註冊證券商、銀行經理、律師、專業會 計師或其他專業顧問。 閣下如已出售或轉讓名下所有上海復宏漢霖生物技術股份有限公司之股份，應立即將本通函連同隨附之代表委任表格 送交買主或承讓人，或經手買賣或轉讓之銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並表明概不就因本通函全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 持續關連交易 重續國控經銷合作 及 臨時股東會通告 獨立董事委員會及獨立股東之獨立財務顧問 本公司謹訂於二零二五年十二月三十一日（星期三）上午九時正假座中國上海市徐匯區宜州路188號B8幢10樓會議室舉 行臨時股東會之通告載於本通函第36頁至37頁。 董事會函件載於本通函第5頁至15頁，而本公司獨立董事委員會致獨立股東 ...

Core Viewpoint - The company, Fuhong Hanlin (02696), has entered into a collaboration agreement with Aohong Pharmaceutical for exclusive commercialization rights of a product in a specific region and field, enhancing its portfolio in the breast cancer treatment market [1] Group 1: Collaboration Agreement - The collaboration agreement was signed on December 3, 2025, following a memorandum of understanding established on August 7, 2025, which met the minimum exemption level under listing rules [1] - The memorandum has been replaced by the collaboration agreement and will automatically terminate on December 3, 2025 [1] Group 2: Product Details - The licensed product, Citric Acid Vofisilib Capsules, is a CDK4/6 inhibitor approved for treating HR+ and HER2– breast cancer [1] - This product aligns with the company's commercialization strategy in the breast cancer sector and has commercial synergies with existing breast cancer pipeline products [1] Group 3: Strategic Benefits - The introduction of the licensed product will enrich the company's pipeline and leverage its existing breast cancer commercialization team and resources to enhance future revenue scale [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 重續國控經銷合作 茲提述本公司於二零二零年四月二十四日及二零二二年十一月十七日刊發的公 告（「該等公告」）以及本公司於二零二零年五月二十八日及二零二二年十二月一 日刊發的通函（「該等通函」），內容有關（其中包括）本公司與國藥控股訂立的國 控經銷框架協議項下的持續關連交易，據此，本公司同意由國藥控股集團作為 本集團部分產品的經銷商之一。 國控經銷框架協議的初始期限已於二零二二年十二月三十一日屆滿。根據國控 經銷框架協議的條款，國控經銷框架協議已自動續期三年，自二零二三年一月 一日起至二零二五年十二月三十一日止，惟須遵守香港上市規則。 本公司與國藥控股擬於二零二五年十二月三十一日後繼續訂立國控經銷框架協 議項下擬進行的交易。訂約方已同意，訂立一份新協議以重續國控經銷合作（國 控經銷框架協議（2025重續）），期限自二零二六年一月一日至二零二八年十二月 三十一日止。根據國控經銷框架協議（2025重續）的條款，其 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 關連交易及持續關連交易 就枸櫞酸伏維西利膠囊與奧鴻藥業訂立合作協議 合作安排 於二零二五年十二月三日，本公司與奧鴻藥業訂立合作協議，據此，奧鴻藥業 同意授予本集團於區域內及領域內商業化運營許可產品的獨家許可權。合作協 議乃於雙方在二零二五年八月七日訂立合作備忘錄（作為上市規則項下符合最低 豁免水平的交易）後訂立，本集團已據合作備忘錄獲得截至雙方正式簽署合作協 議之日期間的過渡期內，許可產品於中國境內的獨家商業化運營權利，合作備 忘錄亦約定雙方將於有關條件具備後訂立正式協議。合作備忘錄已被合作協議 所取代，並於二零二五年十二月三日自動終止。 合作協議的理由及裨益 許可產品（枸櫞酸伏維西利膠囊）作為CDK4/6抑制劑，已獲批用於HR+、 HER2– ...

Market Overview - The Hong Kong stock market experienced a significant decline, with the Hang Seng Index falling by 1.28% to close at 25,760.73 points, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index dropped by 1.68% and 1.58%, respectively [1][2]. Sector Performance - Major technology stocks and large financial stocks collectively dragged down market sentiment, with notable declines in companies like Bilibili (-3%), NetEase (-2.94%), and Alibaba (-2.17%) [4][5]. - The financial sector also faced losses, particularly in insurance stocks, with China Pacific Insurance down by 4% and China Life Insurance down by over 3% [6]. - The biopharmaceutical sector saw declines, with WuXi AppTec falling by over 3% and other major players like BeiGene and WuXi Biologics also experiencing losses [7]. Commodity and Other Stocks - In contrast, stocks in the non-ferrous metals and precious metals sectors performed well, with China Molybdenum and China Aluminum rising by over 2% [8]. - Airline stocks strengthened, with China Eastern Airlines and China Southern Airlines both gaining over 2%, supported by a new action plan promoting the integration of cultural tourism and civil aviation [9]. Capital Flows - Southbound capital saw a net inflow of 2.279 billion HKD, indicating continued interest in Hong Kong stocks from mainland investors [9]. Future Outlook - Analysts suggest that the current market adjustments may create opportunities for recovery in 2026, with expectations of a necessary interest rate cut in December due to rising unemployment and declining real wages [11].

Core Viewpoint - The Hong Kong pharmaceutical stocks experienced a significant downturn, with notable declines in several companies' stock prices [1] Group 1: Company Performance - Gilead Sciences (歌礼制药-B) saw a drop of over 8% in its stock price [1] - Sanofi (圣诺医药-B) experienced a decline of more than 6% [1] - Deciphera Pharmaceuticals (德琪医药-B) fell by over 4% [1] - Other companies such as Innovent Biologics (复宏汉霖) and Antengene Corporation (药捷安康-B) also followed the downward trend [1]

Core Points - The subsidiary of Fosun Pharma, Fuhong Hanlin, has received acceptance for the drug registration application of the biosimilar HLX14, a drug similar to Dexamethasone, by the National Medical Products Administration [1] - The application is classified as a Class 3.3 therapeutic biological product, with indications based on all approved indications of the reference drug Prolia in China [1] Product Information - HLX14 has been approved for marketing in the United States, European Union, and the United Kingdom, covering all indications of the original product [1] - The application for marketing registration was accepted by Health Canada in September 2024 [1] - Cumulative R&D investment is approximately 320 million yuan (unaudited) as of October 2025 [1] Market Outlook - According to IQVIA data, the global sales of Dexamethasone products are projected to be approximately 7.463 billion USD in 2024 [1]